Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Tribune France.
May 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 |
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
Press releases published on June 25, 2025
ABL Diagnostics announces the payment of its first dividend for the 2024 financial year
EIN Presswire
·
June 25, 2025
ABL Diagnostics announces its first dividend for 2024 since the 2022 merger that led activity in the field of genotyping diagnostics of infectious diseases ABL Diagnostics SA (ENX:ABLD) WOIPPY, MOSELLE, FRANCE, June 25, 2025 /EINPresswire.com/ -- The …
Krill Science Hub launches: 20 years of Antarctic research accessible
EIN Presswire
·
June 25, 2025
Krill Science Hub launches as a platform for peer-reviewed and published studies on Antarctica, making essential scientific research accessible to the public. OSLO, OSLO, NORWAY, June 25, 2025 /EINPresswire.com/ -- Krill Science Hub launches as a …
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
GlobeNewswire
·
June 25, 2025
Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatment of active antibody-mediated rejection in kidney …
Communiqué de presse : Le riliprubart est désigné comme médicament orphelin aux États-Unis pour le rejet induit par les anticorps dans la transplantation d’organes solides
GlobeNewswire
·
June 25, 2025
Le riliprubart est désigné comme médicament orphelin aux États-Unis pour le rejet induit par les anticorps dans la transplantation d’organes solides Étude de phase 2 en cours évaluant le riliprubart pour la prévention et le traitement potentiels du rejet …